Targeting heparanase for cancer therapy at the tumor-matrix interface.
Ralph D
RD
Sanderson
Renato V
RV
Iozzo
D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000378:metabolism / Q000494:pharmacology; D005109:Extracellular Matrix / Q000187:drug effects / Q000378:metabolism*; D015972:Gene Expression Regulation, Neoplastic; D005966:Glucuronidase / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D053668:Syndecan-1 / Q000235:genetics / Q000378:metabolism; D059016:Tumor Microenvironment; D000099175:Heparanase
D004791:Enzyme Inhibitors; D005966:Glucuronidase; D053668:Syndecan-1; D000099175:Heparanase; C508241:SDC1 protein, human